Sequence-dependent splicing dysregulation drives therapy resistance in pediatric AML

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Pediatric acute myeloid leukemia (AML) has improved prognosis, but ~30% of patients relapse, facing poor survival.
• The genetic underpinnings of treatment resistance in pediatric AML remain largely unknown.
• Understanding resistance mechanisms is critical for improving patient outcomes.

Purpose of the Study:

• To investigate the mechanistic basis of treatment resistance in pediatric AML.
• To identify genetic factors contributing to relapse and poor survival.
• To uncover novel therapeutic targets for overcoming resistance.

Main Methods:

• Analysis of RNA sequencing (RNA-seq) data from 702 pediatric AML patients.
• Identification and characterization of splicing dysregulation patterns.
• Investigation of the role of U2AF2 in aberrant RNA splicing.

Main Results:

• A sequence-dependent splicing dysregulation was identified in 36% of pediatric AML patients, associated with worse prognosis and lower complete remission rates.
• This aberrant splicing pattern mimics SRSF2 mutations found in adult AML but is driven by U2AF2 dysregulation in pediatric cases.
• Pathologic splicing changes involve "weak" polypyrimidine tracts susceptible to U2AF2 reduction.

Conclusions:

• Aberrant RNA splicing, driven by U2AF2 dysregulation, is a significant factor in pediatric AML treatment resistance.
• Modulating splicing defects, potentially through PRMT enzyme inhibition, offers a promising strategy to improve treatment response.
• Targeting splicing abnormalities represents a novel therapeutic avenue for pediatric AML.